M
Matthew J. LaMarche
Researcher at Novartis
Publications - 79
Citations - 3367
Matthew J. LaMarche is an academic researcher from Novartis. The author has contributed to research in topics: Allosteric regulation & Protein tyrosine phosphatase. The author has an hindex of 31, co-authored 78 publications receiving 2684 citations. Previous affiliations of Matthew J. LaMarche include Albert Einstein College of Medicine & Monell Chemical Senses Center.
Papers
More filters
Journal ArticleDOI
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen,Matthew J. LaMarche,Ho Man Chan,Peter Fekkes,Jorge Garcia-Fortanet,Michael G. Acker,Brandon Antonakos,Chen Christine Hiu-Tung,Zhouliang Chen,Vesselina G. Cooke,Jason R. Dobson,Zhan Deng,Feng Fei,Brant Firestone,Michelle Fodor,Cary Fridrich,Hui Gao,Denise Grunenfelder,Huaixiang Hao,Jaison Jacob,Samuel B. Ho,Kathy Hsiao,Zhao B. Kang,Rajesh Karki,Mitsunori Kato,Jay Larrow,Laura R. La Bonte,Francois Lenoir,Gang Liu,Shumei Liu,Dyuti Majumdar,Matthew J. Meyer,Palermo Mark G,Lawrence Blas Perez,Minying Pu,Edmund Price,Christopher Quinn,Subarna Shakya,Michael Shultz,Joanna Slisz,Kavitha Venkatesan,Ping Wang,Markus Warmuth,Sarah Williams,Guizhi Yang,Jing Yuan,Ji-Hu Zhang,Ping Zhu,Timothy Michael Ramsey,Nicholas Keen,William R. Sellers,Travis Stams,Pascal D. Fortin +52 more
TL;DR: The discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-molecule SHP2 inhibitor, SHP099, that stabilizes SHp2 in an auto-inhibited conformation demonstrates that pharmacological inhibition of SHP1 is a valid therapeutic approach for the treatment of cancers.
Journal ArticleDOI
Evolution of a gram-scale synthesis of (+)-discodermolide
Amos B. Smith,Thomas J. Beauchamp,Matthew J. LaMarche,Michael D. Kaufman,Yuping Qiu,Hirokazu Arimoto,David R. Jones,Kaoru Kobayashi +7 more
TL;DR: An efficient, highly convergent, stereocontrolled total synthesis of the potent antimitotic agent (+)-discodermolide (1) has been achieved on gram scale.
Journal ArticleDOI
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
Jorge Garcia Fortanet,Chen Christine Hiu-Tung,Ying-Nan P. Chen,Zhouliang Chen,Zhan Deng,Brant Firestone,Peter Fekkes,Michelle Fodor,Pascal D. Fortin,Cary Fridrich,Denise Grunenfelder,Samuel B. Ho,Zhao B. Kang,Rajesh Karki,Mitsunori Kato,Nick Keen,Laura R. LaBonte,Jay Larrow,Francois Lenoir,Gang Liu,Shumei Liu,Franco Lombardo,Dyuti Majumdar,Matthew J. Meyer,Palermo Mark G,Lawrence Blas Perez,Minying Pu,Timothy Michael Ramsey,William R. Sellers,Michael Shultz,Travis Stams,Christopher Towler,Ping Wang,Sarah Williams,Ji-Hu Zhang,Matthew J. LaMarche +35 more
TL;DR: The discovery of 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine (SHP099), a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor.
Journal ArticleDOI
Ribosomally synthesized thiopeptide antibiotics targeting elongation factor Tu.
Rowan P. Morris,Jennifer A. Leeds,Hans Ulrich Naegeli,Lukas Oberer,Klaus Memmert,Eric Weber,Matthew J. LaMarche,Christian N. Parker,Nathalie Burrer,Stacey Esterow,Andreas Hein,Esther K. Schmitt,Philipp Krastel +12 more
TL;DR: The thiomuracins are a novel family of thiopeptides produced by a rare-actinomycete bacterium typed as a Nonomuraea species that have a low propensity for selecting for antibiotic resistance and confer no measurable cross-resistance to antibiotics in clinical use.
Journal ArticleDOI
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Leila Dardaei,Hui Qin Wang,Manrose Singh,Paul Fordjour,Katherine X Shaw,Satoshi Yoda,Grainne Kerr,Kristine Yu,Jinsheng Liang,Yichen Cao,Yan Chen,Michael S. Lawrence,Michael S. Lawrence,Adam Langenbucher,Justin F. Gainor,Luc Friboulet,Ibiayi Dagogo-Jack,David T. Myers,Emma Labrot,David A. Ruddy,Melissa Parks,Dana Lee,Richard H. DiCecca,Susan Moody,Huaixiang Hao,Morvarid Mohseni,Matthew J. LaMarche,Juliet Williams,Keith Hoffmaster,Giordano Caponigro,Alice T. Shaw,Aaron N. Hata,Cyril H. Benes,Fang Li,Jeffrey A. Engelman +34 more
TL;DR: Treatment with SHP099, the recently discovered small-molecule inhibitor of SHP2, in combination with the ALK tyrosine kinase inhibitor (TKI) ceritinib halted the growth of resistant PDCs through preventing compensatory RAS and ERk1 and ERK2 (ERK1/2) reactivation.